XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
BIDU-SW
09888
KUAISHOU-W
01024
(FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | (Q6)Jun 30, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | -19.93%122.63M | ---- | 107.58%153.15M | ---- | -22.81%73.78M | ---- | --95.58M | ---- | ---- | 261.50%72.86M |
Profit adjustment | ||||||||||
Interest (income) - adjustment | 12.25%-3.5M | ---- | 55.53%-3.98M | ---- | 62.21%-8.96M | ---- | ---23.7M | ---- | ---- | -473.97%-10.87M |
Interest expense - adjustment | -45.79%8.92M | ---- | -35.55%16.46M | ---- | -46.24%25.53M | ---- | --47.5M | ---- | ---- | -29.56%45.19M |
Attributable subsidiary (profit) loss | ---- | ---- | ---- | ---- | ---- | ---- | --2.86M | ---- | ---- | --1.12M |
Impairment and provisions: | -726.11%-13.29M | ---- | -70.96%2.12M | ---- | 4.96%7.31M | ---- | --6.96M | ---- | ---- | -97.73%1.44M |
-Impairment of trade receivables (reversal) | -339.35%-9.36M | ---- | -54.69%3.91M | ---- | --8.63M | ---- | ---- | ---- | ---- | ---- |
-Impairment of goodwill | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.44M |
-Other impairments and provisions | -119.40%-3.93M | ---- | -35.02%-1.79M | ---- | -119.03%-1.33M | ---- | --6.96M | ---- | ---- | ---- |
Revaluation surplus: | -59.03%6.05M | ---- | -41.12%14.77M | ---- | 12,501.51%25.08M | ---- | --199K | ---- | ---- | -406.81%-21.19M |
-Fair value of investment properties (increase) | -31.43%-17.04M | ---- | -44.27%-12.96M | ---- | 73.26%-8.99M | ---- | ---33.6M | ---- | ---- | -186.80%-5.2M |
-Other fair value changes | -16.74%23.09M | ---- | -18.59%27.73M | ---- | 0.78%34.06M | ---- | --33.8M | ---- | ---- | -1,838.26%-15.99M |
Asset sale loss (gain): | 78.65%-415K | ---- | ---1.94M | ---- | ---- | ---- | --445K | ---- | ---- | -14,111.58%-13.5M |
-Available for sale investment sale loss (gain) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -3,136.84%-2.46M |
-Loss (gain) from sale of subsidiary company | 78.41%-422K | ---- | ---1.96M | ---- | ---- | ---- | ---- | ---- | ---- | ---11.04M |
-Loss (gain) on sale of property, machinery and equipment | -36.36%7K | ---- | --11K | ---- | ---- | ---- | --445K | ---- | ---- | ---- |
Depreciation and amortization: | 5.17%4.19M | ---- | -37.57%3.98M | ---- | -34.06%6.38M | ---- | --9.68M | ---- | ---- | 103.98%8.91M |
-Amortization of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -67.01%287K |
Special items | ---- | ---- | -23,556.88%-63.1M | ---- | -84.06%269K | ---- | --1.69M | ---- | ---- | 314.30%6.46M |
Operating profit before the change of operating capital | 2.59%124.59M | ---- | -6.13%121.45M | ---- | -8.37%129.39M | ---- | --141.2M | ---- | ---- | -2.98%90.43M |
Change of operating capital | ||||||||||
Accounts receivable (increase)decrease | 408.22%151.25M | ---- | ---49.07M | ---- | ---- | ---- | ---15.36M | ---- | ---- | 235.67%9.85M |
Accounts payable increase (decrease) | 80.95%-2.63M | ---- | 84.19%-13.82M | ---- | -21.45%-87.4M | ---- | ---71.97M | ---- | ---- | 40.07%-105.6M |
prepayments (increase)decrease | 69.87%73.15M | ---- | 10,578.10%43.07M | ---- | 99.19%-411K | ---- | ---50.61M | ---- | ---- | -56.93%14.5M |
Cash from business operations | 240.81%346.37M | ---- | 144.46%101.63M | ---- | 1,172.51%41.57M | ---- | --3.27M | ---- | ---- | 116.23%9.18M |
Special items of business | ---- | 77.70%158.76M | ---- | 389.12%89.34M | ---146.37M | 1,575.44%18.27M | ---- | 93.50%-1.24M | 93.50%-1.24M | ---- |
Net cash from operations | 240.81%346.37M | 77.70%158.76M | 196.97%101.63M | 389.12%89.34M | -3,307.87%-104.8M | 1,575.44%18.27M | --3.27M | 93.50%-1.24M | 93.50%-1.24M | 116.23%9.18M |
Cash flow from investment activities | ||||||||||
Interest received - investment | 2,508.21%3.5M | ---- | -98.50%134K | ---- | 10.48%8.96M | ---- | --8.11M | ---- | ---- | 47.88%1.89M |
Loan receivable (increase) decrease | ---- | ---- | -99.48%1.14M | ---- | 236.72%221.73M | ---- | ---162.17M | ---- | ---- | 152.05%37.21M |
Sale of fixed assets | --29K | ---- | ---- | ---- | ---- | ---- | --435K | ---- | ---- | --57K |
Purchase of fixed assets | 63.24%-1.93M | ---- | -796.75%-5.24M | ---- | -68.30%-584K | ---- | ---347K | ---- | ---- | 80.05%-1.24M |
Purchase of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---193K | ---- | ---- | ---- |
Sale of subsidiaries | -72.99%430K | ---- | --1.59M | ---- | ---- | ---- | ---- | ---- | ---- | ---270K |
Acquisition of subsidiaries | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -205.28%-3.99M |
Recovery of cash from investments | ---- | ---- | -82.19%86K | ---- | 237.76%483K | ---- | --143K | ---- | ---- | 714.52%4.55M |
Cash on investment | 56.10%-7.02M | ---- | 61.15%-16M | ---- | ---41.18M | ---- | ---- | ---- | ---- | ---- |
Other items in the investment business | -20.38%58.39M | 98.50%-1.59M | --73.33M | -226.81%-105.72M | ---- | -62.74%83.37M | --55.88M | 9,449.77%223.74M | 9,449.77%223.74M | ---- |
Net cash from investment operations | -3.02%53.39M | 98.50%-1.59M | -70.93%55.05M | -226.81%-105.72M | 292.97%189.41M | -62.74%83.37M | ---98.15M | 9,449.77%223.74M | 9,449.77%223.74M | 126.83%38.2M |
Net cash before financing | 155.14%399.76M | 1,059.65%157.17M | 85.19%156.68M | -116.11%-16.38M | 189.17%84.61M | -54.32%101.64M | ---94.89M | 1,138.27%222.5M | 1,138.27%222.5M | 123.82%47.38M |
Cash flow from financing activities | ||||||||||
New borrowing | ---- | ---- | ---- | ---- | -19.90%169.75M | ---- | --211.93M | ---- | ---- | 10.75%454.98M |
Refund | 85.06%-15.47M | ---- | 47.74%-103.54M | ---- | 57.51%-198.12M | ---- | ---466.25M | ---- | ---- | -100.43%-524.06M |
Issuing shares | --149.76M | ---- | ---- | ---- | ---- | ---- | --307.23M | ---- | ---- | ---- |
Interest paid - financing | 35.89%-9.71M | ---- | -29.39%-15.15M | ---- | 60.70%-11.71M | ---- | ---29.79M | ---- | ---- | ---- |
Issuance expenses and redemption of securities expenses | -32.63%-7.96M | ---- | -500.00%-6M | ---- | 97.04%-1M | ---- | ---33.83M | ---- | ---- | ---98.17M |
Other items of the financing business | ---- | 604.08%132.64M | ---- | 151.68%18.84M | ---- | 81.52%-36.45M | ---- | 20.28%-197.22M | 20.28%-197.22M | -2.50%-25.45M |
Net cash from financing operations | 189.00%114.01M | 604.08%132.64M | -175.06%-128.09M | 151.68%18.84M | -156.38%-46.57M | 81.52%-36.45M | ---18.16M | 20.28%-197.22M | 20.28%-197.22M | -142.73%-199.92M |
Effect of rate | -79.70%-6.13M | -48.72%-9.19M | -155.08%-3.41M | -226.99%-6.18M | 349.71%6.2M | 463.06%4.87M | --1.38M | -2,171.19%-1.34M | -2,171.19%-1.34M | -28.79%1.37M |
Net Cash | 1,697.00%513.76M | 11,680.73%289.81M | -24.84%28.59M | -96.23%2.46M | 133.65%38.04M | 157.86%65.19M | ---113.05M | 109.40%25.28M | 109.40%25.28M | -156.73%-152.54M |
Begining period cash | 43.47%83.09M | 43.47%83.09M | 323.36%57.92M | 323.36%57.92M | -89.09%13.68M | -89.09%13.68M | --125.35M | -54.67%125.35M | -54.67%125.35M | 4,752.27%276.53M |
Cash at the end | 610.93%590.72M | 571.09%363.71M | 43.47%83.09M | -35.27%54.2M | 323.36%57.92M | -43.91%83.73M | --13.68M | 1,849.22%149.29M | 1,849.22%149.29M | -54.67%125.35M |
Cash balance analysis | ||||||||||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- | -- |
Auditor | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | Guofu Haohua (Hong Kong) Certified Public Accountants Limited | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.